Hormonal
GLP-1RAs modulate T cell differentiation by reducing the proportion of pro-inflammatory Th17 cells and increasing regulatory T cells (Tregs), thereby improving immune tolerance and reducing inflammation in conditions like psoriasis and colitis.
For those with autoimmune conditions, GLP-1RAs may help rebalance your immune system by reducing inflammatory T cells and boosting regulatory ones. This could potentially complement standard treatments by addressing the underlying immune imbalance.
Activation of T cells in the context of Th1-polarizing and Th17-polarizing requirements with the GLP-1RA liraglutide led to reduced differentiation of Th1 and Th17 cells... GLP-1RAs like exenatide notably decreased the percentage of Th17 cells while promoting the proliferation of Tregs.
Why this rating
Evidence is from in vitro and in vivo animal models (mice), with some clinical correlation mentioned (psoriasis severity), but no large-scale human RCTs for autoimmune endpoints are detailed in this text.
Source
Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune/autoinflammatory diseases
Sihui Deng et al. · Cell & Bioscience · 2025
DOI 10.1186/s13578-025-01486-8
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) exert immunoregulatory effects by promoting the polarization of macrophages and microglia from a pro-inflammatory M1 phenotype to an anti-inflammatory M2 phenotype, thereby reducing neuroinflammation and systemic inflammatory markers.Moderate
- GLP-1RAs reduce innate allergic inflammation and eosinophilia by inhibiting the activity of Group 2 Innate Lymphoid Cells (ILC2s) and reducing the production of type 2 cytokines (IL-5, IL-13).Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →